RIL
STIM icon

Rothschild Investment LLC’s Neuronetics STIM Stock Holding History

Rothschild Investment LLC’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108 Buy
83
+28
+51% +$41 ﹤0.01% 3506
2026
Q1 		$80 Buy
+55
New +$87 ﹤0.01% 3419

Other funds holding STIM

MAM
Madryn Asset Management New York $36.9M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rothschild Investment LLC's STIM Position: Q2 2026 in Review

Rothschild Investment LLC increased its Neuronetics (STIM) stake by 51% in Q2 2026, buying an estimated $41 and bringing the position to 83 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #3506.

Rothschild Investment LLC first reported a position in STIM in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold STIM as of Q2 2026.

  • Rothschild Investment LLC held 83 shares of Neuronetics worth $108 as of Q2 2026.
  • Rothschild Investment LLC bought 28 Neuronetics shares in Q2 2026, an estimated $41.
  • Neuronetics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3506 holding.
  • Rothschild Investment LLC first reported a position in Neuronetics in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Neuronetics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.